Literature DB >> 8933003

Insulin resistance and coronary artery disease.

P Bressler1, S R Bailey, M Matsuda, R A DeFronzo.   

Abstract

The purpose of the present study was to quantitate insulin-mediated glucose disposal in normal glucose tolerant patients with angiographically documented coronary artery disease (CAD) and to define the pathways responsible for the insulin resistance. We studied 13 healthy, normal weight, normotensive subjects with angiographically documented CAD and 10 age-, weight-matched control subjects with an oral glucose tolerance test and a 2-h euglycaemic insulin (40 mU.m-2.min-1) clamp with tritiated glucose and indirect calorimetry. Lean body mass was measured with tritiated water. All CAD and control subjects had a normal oral glucose tolerance test. Fasting plasma insulin concentration (66 +/- 6 vs 42 +/- 6 pmol/l, p < 0.05) and area under the plasma insulin curve following glucose ingestion (498 +/- 54 vs 348 +/- 42 pmol.l-1.min-1, p < 0.001) were increased in CAD vs control subjects. Insulin-mediated whole body glucose disposal (27.8 +/- 3.9 vs 38.3 +/- 4.4 mumol.kg fat free mass (FFM)-1.min-1, p < 0.01) was significantly decreased in CAD subjects and this was entirely due to diminished non-oxidative glucose disposal (8.9 +/- 2.8 vs 20.0 +/- 3.3 mumol.kg FFM-1.min-1, p < 0.001). The magnitude of insulin resistance was positively correlated with the severity of CAD (r = 0.480, p < 0.05). In the CAD subjects basal and insulin-mediated rates of glucose and lipid oxidation were normal and insulin caused a normal suppression of hepatic glucose production. In conclusion, subjects with angiographically documented CAD are characterized by moderate-severe insulin resistance and hyperinsulinaemia and should be included in the metabolic and cardiovascular cluster of disorders that comprise the insulin resistance syndrome or "syndrome X'.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8933003     DOI: 10.1007/s001250050581

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  32 in total

1.  Sympathetic overactivity precedes metabolic dysfunction in a fructose model of glucose intolerance in mice.

Authors:  Katia De Angelis; Danielle D Senador; Cristiano Mostarda; Maria C Irigoyen; Mariana Morris
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-02-08       Impact factor: 3.619

2.  Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease.

Authors:  V D F de Mello; M Lankinen; U Schwab; M Kolehmainen; S Lehto; T Seppänen-Laakso; M Oresic; L Pulkkinen; M Uusitupa; A T Erkkilä
Journal:  Diabetologia       Date:  2009-08-11       Impact factor: 10.122

3.  Surrogate markers of insulin resistance: A review.

Authors:  Bhawna Singh; Alpana Saxena
Journal:  World J Diabetes       Date:  2010-05-15

Review 4.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

Review 5.  Pathogenesis of insulin resistance in skeletal muscle.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  J Biomed Biotechnol       Date:  2010-04-26

Review 6.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.

Authors:  R A DeFronzo
Journal:  Diabetologia       Date:  2010-04-02       Impact factor: 10.122

7.  Saturated-fat diet induces moderate diabetes and severe glomerulosclerosis in hamsters.

Authors:  D Popov; M Simionescu; P R Shepherd
Journal:  Diabetologia       Date:  2003-07-29       Impact factor: 10.122

8.  Selective association of electrocardiographic abnormalities with insulin sensitivity and beta-cell function in type 2 diabetes mellitus: a cross-sectional analysis.

Authors:  Anish B Bhatt; Claire K Mulvey; Atif N Qasim; Jayamohan V Nair; Michael R Rickels; Stuart B Prenner; Nayyar Iqbal; Muredach P Reilly
Journal:  Diabetes Metab Res Rev       Date:  2016-04-21       Impact factor: 4.876

9.  Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome.

Authors:  Georgia Trakada; Paschalis Steiropoulos; Evangelia Nena; Theodora Gkioka; Georgios Kouliatsis; Athanasia Pataka; Ioannis Sotiriou; Stavros Anevlavis; Nikolaos Papanas; Demosthenes Bouros
Journal:  Sleep Breath       Date:  2009-04-10       Impact factor: 2.816

10.  The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.

Authors:  Necati Dagli; Mustafa Yavuzkir; Ilgin Karaca
Journal:  Inflammation       Date:  2007-08-09       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.